Stockhouse.com: Taking it to the street
Boards & Blogs
Active Resource Stocks
Natural Resources Bulletins
Natural Resources Wire
US Press Releases
Canadian Press Releases
Showcase News Releases
Tools & Resources
Jobs / Careers
Blogs at a Glance
My Favorite Blogs
CEO Interview & Company Overview
Northern Vertex | V.NEE
Other Recent Video
CEO Interview and Company Overview
Sniper Resources Ltd. | V.SIP
Breaking News: Kootenay Closes $8,253,850 Private Placement Financing
Kootenay Silver Inc. | V.KTN
Visit the Video Showcase
MissionIR Small-Cap Blog
add to favorites
Advanced Cell Technology, Inc. (ACTC) Continues Clinical Trials; Receives $35 Million...
posted on 10/23/2012 2:34:18 PM | 117 reads | Post #154838
overall quality :
Average quality rating by the Stockhouse community.
Advanced Cell Technology, Inc. (ACTC) Continues Clinical Trials; Receives $35 Million Funding Commitment
Advanced Cell Technology, a leader in the field of regenerative medicine, recently announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.
“Our progress continues in our European clinical trial and both our trials in the U.S., as seen most recently with last week’s announcement of treatment of the second patient in the second patient cohort of our U.S. trial for SMD,” said Gary Rabin, chairman and CEO of ACTC. “As I mentioned last week, we have mapped out the series of patients to complete the second cohort of both our trials for SMD, as well as for our trial for dry age-related macular degeneration (dry AMD), pending DSMB review, and we anticipate generating patient data at a faster pace.”
ACTC, known as a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide, is excited about the trial’s progress. Having only been initiated in January, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study’s primary endpoint.
ACTC also recently announced that it had entered into a $35 million common stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor. Proceeds from this transaction will be used to fund the company’s clinical activities, including its three ongoing Phase I/II clinical trials for forms of macular degeneration, for development of its other clinical activities, and for general corporate purposes.
“We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of ACTC. “Lincoln Park Capital is an excellent partner for us with a great track record and a long-term commitment to the life sciences field. This transaction offers the Company a very cost efficient and readily available form of financing. The $35 million available under the agreement equates to more than two years of funding for the Company, even assuming no other sources of capital. It was a priority for us to complete a new financing by year-end, as we never again want to be in a position to have to go looking for capital from a position of distress or weakness. This agreement strengthens our balance sheet allowing us to focus on advancing our clinical programs, pursuing strategic partnerships, and other long-term objectives.”
For more information on ACTC, visit
Please see disclaimer on the MissionIR website
add to favorites
login to comment
Featured News Links
Empire Industries announces Private Placement and creation of a 51% controlled Chinese JV
Top three reasons why you need to invest in this company
Game changer for Pangolin Diamonds, as explorer becomes discoverer of first kimberlite in Botswana
Kootenay drill program closes in on 100+ M Silver Eqv Milestone!
Register for the Vancouver Resource Investment Conference – May 26-27, 2013
Pacific North West Capital Corp.
Pacific North West Capital Corp. (TSX: PFN; OTCQX: PAWEF; Frankfurt: P7J)
is a mineral exploration company focused on the discovery, exploration and development of PGM and nickel-copper sulphide deposits in geologically prospective regions in North America, particularly Canada. The Company's key asset is its 100% owned River Valley PGM Project in the Sudbury region of northern Ontario. The River Valley Project is one of North America's most advanced primary PGM deposits...
Stockhouse.com is owned by
Stockhouse Publishing Ltd.
Financial Market Data powered by
All rights reserved. View the
NYSE/AMEX/NASDAQ and other data delayed 15 minutes unless otherwise indicated.
© 2013 Stockhouse publishing Ltd. All rights reserved. |